SCHEMBL18274692

SCHEMBL18274692

CC(CN)OC(=O)[C@H](C)N

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.35
▸ LMNA P02545 3/20 0.34
▸ CYP2C9 P11712 2/20 0.34
▸ CHRM2 P08172 2/20 0.34
▸ CHRM4 P08173 2/20 0.34
▸ CHRM1 P11229 2/20 0.34
▸ TSHR P16473 2/20 0.34
▸ CHRM5 P08912 1/20 0.34
▸ CHRM3 P20309 1/20 0.34
▸ MAPT P10636 2/20 0.33
▸ GRIN2D O15399 1/20 0.33
▸ GRIN3B O60391 1/20 0.33
▸ GRIN1 Q05586 1/20 0.33
▸ GRIN2A Q12879 1/20 0.33
▸ GRIN2B Q13224 1/20 0.33
▸ GRIN2C Q14957 1/20 0.33
▸ GRIN3A Q8TCU5 1/20 0.33
▸ CHRNB2 P17787 1/20 0.32
▸ CHRNB4 P30926 1/20 0.32
▸ CHRNA3 P32297 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL11516935 0.98 LMNA (0.33) ALDH1A1LMNACYP2C9CHRM2CHRM4
Hydrochloric Acid SCHEMBL3506816 0.86 LMNA (0.34) LMNACYP2C9CHRM2CHRM4CHRM1
Hydrochloric Acid SCHEMBL3507188 0.86 LMNA (0.34) LMNACYP2C9CHRM2CHRM4CHRM1
Hydrochloric Acid SCHEMBL3506823 0.86 LMNA (0.34) LMNACYP2C9CHRM2CHRM4CHRM1
SCHEMBL23656867 0.81 SLC7A5 (0.44) ALDH1A1LMNACYP2C9CHRM2CHRM4
SCHEMBL14989440 0.81 MAPT (0.41) ALDH1A1LMNACYP2C9CHRM2CHRM4
SCHEMBL14887353 0.81 MAPT (0.41) ALDH1A1LMNACYP2C9CHRM2CHRM4
SCHEMBL15574890 0.81 MAPT (0.41) ALDH1A1LMNACYP2C9CHRM2CHRM4
SCHEMBL14989441 0.81 MAPT (0.41) ALDH1A1LMNACYP2C9CHRM2CHRM4
SCHEMBL14887474 0.81 MAPT (0.41) ALDH1A1LMNACYP2C9CHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10919840-B2 Diamine crosslinking agents, crosslinked acidic polysaccharides and medical materials SEIKAGAKU CORPORATION (JP) 2021-02-16 — — US disclosed
US-10919840-B2 Diamine crosslinking agents, crosslinked acidic polysaccharides and medical materials SEIKAGAKU CORPORATION (JP) 2021-02-16 — — US disclosed
EP-3101064-B1 DIAMINE CROSSLINKING AGENT, ACIDIC POLYSACCHARIDE CROSSLINKED BODY, AND MEDICAL MATERIAL SEIKAGAKU KOGYO CO LTD (JP) 2020-07-15 — — EP disclosed
US-20190345312-A1 DIAMINE CROSSLINKING AGENTS, CROSSLINKED ACIDIC POLYSACCHARIDES AND MEDICAL MATERIALS SEIKAGAKU CORPORATION (JP) 2019-11-14 — — US disclosed
US-20190345312-A1 DIAMINE CROSSLINKING AGENTS, CROSSLINKED ACIDIC POLYSACCHARIDES AND MEDICAL MATERIALS SEIKAGAKU CORPORATION (JP) 2019-11-14 — — US disclosed
US-10294195-B2 Diamine crosslinking agents, crosslinked acidic polysaccharides and medical materials SEIKAGAKU CORPORATION (JP) 2019-05-21 — — US disclosed
US-10294195-B2 Diamine crosslinking agents, crosslinked acidic polysaccharides and medical materials SEIKAGAKU CORPORATION (JP) 2019-05-21 — — US disclosed
US-20170001948-A1 DIAMINE CROSSLINKING AGENTS, CROSSLINKED ACIDIC POLYSACCHARIDES AND MEDICAL MATERIALS SEIKAGAKU CORPORATION (JP) 2017-01-05 — — US disclosed
US-20170001948-A1 DIAMINE CROSSLINKING AGENTS, CROSSLINKED ACIDIC POLYSACCHARIDES AND MEDICAL MATERIALS SEIKAGAKU CORPORATION (JP) 2017-01-05 — — US disclosed
US-20170001948-A1 DIAMINE CROSSLINKING AGENTS, CROSSLINKED ACIDIC POLYSACCHARIDES AND MEDICAL MATERIALS SEIKAGAKU CORPORATION (JP) 2017-01-05 — — US disclosed
EP-3101064-A1 DIAMINE CROSSLINKING AGENT, ACIDIC POLYSACCHARIDE CROSSLINKED BODY, AND MEDICAL MATERIAL Seikagaku Corporation (JP) 2016-12-07 — — EP disclosed
EP-3101064-A1 DIAMINE CROSSLINKING AGENT, ACIDIC POLYSACCHARIDE CROSSLINKED BODY, AND MEDICAL MATERIAL Seikagaku Corporation (JP) 2016-12-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10294195-B2 Diamine crosslinking agents, crosslinked acidic polysaccharides and medical materials SAT1, ACMSD, ADM2 ALDH1A1 293/4885LMNA 3691/4885CYP2C9 2588/4885
US-20170001948-A1 DIAMINE CROSSLINKING AGENTS, CROSSLINKED ACIDIC POLYSACCHARIDES AND MEDICAL MATERIALS SAT1, ACMSD, ADM2 ALDH1A1 293/4885LMNA 3691/4885CYP2C9 2588/4885
US-10919840-B2 Diamine crosslinking agents, crosslinked acidic polysaccharides and medical materials SAT1, ACMSD, ADM2 ALDH1A1 293/4885LMNA 3691/4885CYP2C9 2588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback